KZIA Latest Press Releases

-- November 2, 2026 --

Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium PRNewswire 7:00 AM

-- October 29, 2026 --

Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference PRNewswire 7:01 AM

-- September 22, 2026 --

Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders PRNewswire 7:31 AM

-- September 9, 2026 --

Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer PRNewswire 7:30 AM

-- September 1, 2026 --

Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy PRNewswire 7:30 AM

Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer PRNewswire 7:15 AM

-- August 31, 2026 --

Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering PRNewswire 5:59 PM

-- August 28, 2026 --

Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering PRNewswire 7:30 AM

-- August 27, 2026 --

Kazia Therapeutics Limited Announces Proposed Public Offering PRNewswire 4:10 PM

Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer PRNewswire 4:02 PM

-- July 28, 2026 --

Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer Globe Newswire 7:30 AM

-- June 3, 2026 --

The Multi-Billion-Dollar Search for Better Glioblastoma Treatments Globe Newswire 9:28 AM

Market Data Delayed 15 Minutes